...
首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Determination of genetic predisposition to patent ductus arteriosus in preterm infants.
【24h】

Determination of genetic predisposition to patent ductus arteriosus in preterm infants.

机译:确定早产儿动脉导管未闭的遗传易感性。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: Patent ductus arteriosus is a common morbidity associated with preterm birth. The incidence of patent ductus arteriosus increases with decreasing gestational age to approximately 70% in infants born at 25 weeks' gestation. Our major goal was to determine if genetic risk factors play a role in patent ductus arteriosus seen in preterm infants. METHODOLOGY: We investigated whether single-nucleotide polymorphisms in genes that regulate smooth muscle contraction, xenobiotic detoxification, inflammation, and other processes are markers for persistent patency of ductus arteriosus. Initially, 377 single-nucleotide polymorphisms from 130 genes of interest were evaluated in DNA samples collected from 204 infants with a gestational age of <32 weeks. A family-based association test was performed on genotyping data to evaluate overtransmission of alleles. RESULTS: P values of <.01 were detected for genetic variations found in 7 genes. This prompted additional analysis with an additional set of 162 infants, focusing on the 7 markers with initial P values of <.01, and 1 genetic variant in the angiotensin II type I receptor previously shown to be related to patent ductus arteriosus. Of the initial positive signals, single-nucleotide polymorphisms in the transcription factor AP-2 beta and tumor necrosis factor receptor-associated factor 1 genes remained significant. Additional haplotype analysis revealed genetic variations in prostacyclin synthase to be associated with patent ductus arteriosus. An angiotensin II type I receptor polymorphism previously reported to be associated with patent ductus arteriosus after prophylactic indomethacin administration was not associated with the presence of a patent ductus arteriosus in our population. CONCLUSIONS: Overall, our data support a role for genetic variations in transcription factor AP-2 beta, tumor necrosis factor receptor-associated factor 1, and prostacyclin synthase in the persistent patency of the ductus arteriosus seen in preterm infants.
机译:目的:动脉导管未闭是早产的常见病。在妊娠25周时出生的婴儿中,动脉导管未闭的发生率随着胎龄的降低而增加,达到约70%。我们的主要目标是确定遗传风险因素是否在早产儿所见的动脉导管未闭中起作用。方法:我们研究了调节平滑肌收缩,异种生物排毒,炎症和其他过程的基因中的单核苷酸多态性是否是动脉导管持续通畅的标志。最初,在从204个胎龄小于32周的婴儿中收集的DNA样品中评估了来自130个目的基因的377个单核苷酸多态性。对基因分型数据进行了基于家庭的关联测试,以评估等位基因的过度传递。结果:在7个基因中发现的遗传变异的P值均<.01。这促使我们对另外162名婴儿进行了进一步分析,重点关注7个初始P值均<.01的标记物,以及先前显示与动脉导管未闭相关的I型血管紧张素II受体的1个遗传变异。在最初的阳性信号中,转录因子AP-2 beta和肿瘤坏死因子受体相关因子1基因中的单核苷酸多态性仍然很显着。其他单倍型分析显示前列环素合酶的遗传变异与动脉导管未闭有关。先前报道的预防性消炎痛给药后,血管紧张素II型I型受体多态性与动脉导管未闭相关,在我们的人群中与动脉导管未闭相关。结论:总体而言,我们的数据支持早产儿动脉导管持续通畅中转录因子AP-2 beta,肿瘤坏死因子受体相关因子1和前列环素合酶遗传变异的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号